|
Should adverse effects be adjusted for multiple comparisons?
|
|
4
|
212
|
May 24, 2022
|
|
Individual response
|
|
114
|
10858
|
May 17, 2022
|
|
Quality of remdesivir trials
|
|
51
|
8375
|
May 12, 2022
|
|
Background to PFS endpoint
|
|
16
|
802
|
May 8, 2022
|
|
Summary Statistics vs Raw Data
|
|
8
|
3754
|
May 7, 2022
|
|
Methodology: Benefit Risk Assessment when Risk and Benefit are only observed in different timing
|
|
5
|
383
|
April 18, 2022
|
|
Covariate adjustment in non-inferiority trials
|
|
3
|
236
|
April 14, 2022
|
|
RCT and "Mathematical Embellishment"
|
|
2
|
493
|
April 5, 2022
|
|
Chi-Squared for relative risk
|
|
1
|
361
|
March 27, 2022
|
|
Analysis of 2x2 trial with anticipated treatment interaction
|
|
9
|
1980
|
March 25, 2022
|
|
How to calculate number of events in each treatment arm given hazard ratio and CI?
|
|
2
|
520
|
March 6, 2022
|
|
Language for communicating frequentist results about treatment effects
|
|
194
|
69349
|
March 3, 2022
|
|
Covariate imbalance in RCT
|
|
5
|
566
|
February 23, 2022
|
|
Estimate treatment effect in study with a composite complication score as outcome
|
|
9
|
752
|
February 18, 2022
|
|
Single cluster cluster randomized crossover (CRXO) design?
|
|
3
|
567
|
February 17, 2022
|
|
Bernoulli trials vs completely randomized trials
|
|
0
|
610
|
January 5, 2022
|
|
Catastrophic Heterogeneity Meets "The Clairvoyant RCT"
|
|
0
|
743
|
December 28, 2021
|
|
Cost-effectiveness based interim analysis
|
|
2
|
656
|
December 15, 2021
|
|
Interpretation of the REGEN-COV trial
|
|
22
|
3127
|
November 1, 2021
|
|
Evidence Based Decision Making and Meta-Analysis -- An Information Theoretic Critique
|
|
0
|
1023
|
October 27, 2021
|
|
First RCT of Lopinavir–Ritonavir on SARS-CoV2
|
|
38
|
11449
|
October 8, 2021
|
|
Extensions of 'worst-rank' score methods with outcomes truncated by death
|
|
13
|
1308
|
September 2, 2021
|
|
Resources for Mixed-Effect Models in Medical Contexts
|
|
7
|
1445
|
August 8, 2021
|
|
Heterogeneity in RCTs with continuous outcome
|
|
19
|
3091
|
July 2, 2021
|
|
Default Using R package to implement Bayesian phase I/II dose-finding design for three outcomes
|
|
10
|
1662
|
June 10, 2021
|
|
Multiplicity in clinical trials with hierarchical strategy
|
|
2
|
2083
|
December 30, 2020
|
|
What is a fake measurement tool and how are they used in RCT
|
|
44
|
7369
|
December 20, 2020
|
|
RCT trials for COVID study vaccines
|
|
0
|
1750
|
October 24, 2020
|
|
Can treatment B be superior after the RCT if it was thought that treatment A is superior before the RCT?
|
|
5
|
1978
|
October 13, 2020
|
|
"Open label, double-masked trial"
|
|
0
|
1950
|
October 13, 2020
|